523 related items for PubMed ID: 16145319
1. Effect of hormone therapy on the enteroinsular axis.
Sztefko K, Rogatko I, Milewicz T, Józef K, Tomasik PJ, Szafran Z.
Menopause; 2005; 12(5):630-638. PubMed ID: 16145319
[Abstract] [Full Text] [Related]
2. [Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol].
Milewicz T, Kostecka A, Rogatko I, Sztefko K, Kwiatkowska-Panek E, Radowick S, Krzysiek J.
Przegl Lek; 2007; 64(2):65-9. PubMed ID: 17892034
[Abstract] [Full Text] [Related]
3. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.
Chiantera V, Sarti CD, Fornaro F, Farzati A, De Franciscis P, Sepe E, Borrelli AL, Colacurci N.
Menopause; 2003; 10(4):286-91. PubMed ID: 12851511
[Abstract] [Full Text] [Related]
4. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women.
Godsland IF, Manassiev NA, Felton CV, Proudler AJ, Crook D, Whitehead MI, Stevenson JC.
Clin Endocrinol (Oxf); 2004 May; 60(5):541-9. PubMed ID: 15104556
[Abstract] [Full Text] [Related]
5. Insulin sensitivity during postmenopausal hormone replacement with transdermal estradiol and intrauterine levonorgestrel.
Raudaskoski T, Tomás C, Laatikainen T.
Acta Obstet Gynecol Scand; 1999 Jul; 78(6):540-5. PubMed ID: 10376866
[Abstract] [Full Text] [Related]
6. Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study.
Davis SR, Stuckey BG, Norman RJ, Papalia MA, Drillich A, Bell RJ.
Menopause; 2008 Jul; 15(6):1065-9. PubMed ID: 18806686
[Abstract] [Full Text] [Related]
7. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S, Zochowska E, Safranow K, Sieja K, Stanosz M.
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[Abstract] [Full Text] [Related]
8. Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus.
Araújo DA, Farias ML, Andrade AT.
Climacteric; 2002 Sep; 5(3):286-92. PubMed ID: 12419087
[Abstract] [Full Text] [Related]
9. Plasma adiponectin levels in postmenopausal women with or without long-term hormone therapy.
Im JA, Lee JW, Lee HR, Lee DC.
Maturitas; 2006 Apr 20; 54(1):65-71. PubMed ID: 16198517
[Abstract] [Full Text] [Related]
10. B-type natriuretic peptide after hormone therapy in postmenopausal women with chest pain and normal coronary angiogram.
Kawano H, Nagayoshi Y, Soejima H, Tanaka Y, Hokamaki J, Miyamoto S, Miyazaki Y, Yamabe H, Ogawa H.
Menopause; 2008 Apr 20; 15(2):352-6. PubMed ID: 18090872
[Abstract] [Full Text] [Related]
11. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome.
Chu MC, Cosper P, Nakhuda GS, Lobo RA.
Fertil Steril; 2006 Dec 20; 86(6):1669-75. PubMed ID: 17074346
[Abstract] [Full Text] [Related]
12. The effect of postmenopausal hormone therapy with or without folic acid supplementation on serum homocysteine level.
Toprak A, Erenus M, Ilhan AH, Haklar G, Fak AS, Oktay A.
Climacteric; 2005 Sep 20; 8(3):279-86. PubMed ID: 16390760
[Abstract] [Full Text] [Related]
13. Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy.
Maffei S, Mercuri A, Prontera C, Zucchelli GC, Vassalle C.
Climacteric; 2006 Dec 20; 9(6):452-8. PubMed ID: 17085378
[Abstract] [Full Text] [Related]
14. Different effects of oral conjugated equine estrogens and transdermal estrogen on undercarboxylated osteocalcin concentration in postmenopausal women.
Yasui T, Uemura H, Tomita J, Umino Y, Yamada M, Kuwahara A, Matsuzaki T, Maegawa M, Miura M, Irahara M.
Menopause; 2006 Dec 20; 13(4):651-9. PubMed ID: 16837887
[Abstract] [Full Text] [Related]
15. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women.
O'Sullivan AJ, Crampton LJ, Freund J, Ho KK.
J Clin Invest; 1998 Sep 01; 102(5):1035-40. PubMed ID: 9727072
[Abstract] [Full Text] [Related]
16. Plasma leptin in postmenopausal women with coronary artery disease: effect of transdermal 17beta-estradiol and intermittent medroxyprogesterone acetate.
Os I, Os A, Abdelnoor M, Larsen A, Birkeland K, Westheim A.
Climacteric; 2003 Sep 01; 6(3):204-10. PubMed ID: 14567768
[Abstract] [Full Text] [Related]
17. Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome.
Zwirska-Korczala K, Konturek SJ, Sodowski M, Wylezol M, Kuka D, Sowa P, Adamczyk-Sowa M, Kukla M, Berdowska A, Rehfeld JF, Bielanski W, Brzozowski T.
J Physiol Pharmacol; 2007 Mar 01; 58 Suppl 1():13-35. PubMed ID: 17443025
[Abstract] [Full Text] [Related]
18. Effects of postmenopausal hormone replacement therapy on body fat composition.
Yüksel H, Odabasi AR, Demircan S, Köseoğlu K, Kizilkaya K, Onur E.
Gynecol Endocrinol; 2007 Feb 01; 23(2):99-104. PubMed ID: 17454160
[Abstract] [Full Text] [Related]
19. Effect of oral or transdermal hormone replacement therapy on homocysteine levels: a randomized clinical trial.
Bruschi F, Dal Pino D, Fiore V, Parazzini F, Di Pace R, Cesana BM, Melotti D, Crosignani PG.
Maturitas; 2004 May 28; 48(1):33-8. PubMed ID: 15223106
[Abstract] [Full Text] [Related]
20. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study.
Sonnet E, Lacut K, Roudaut N, Mottier D, Kerlan V, Oger E.
Clin Endocrinol (Oxf); 2007 May 28; 66(5):626-31. PubMed ID: 17492948
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
